(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
Public ClinicalTrials.gov record NCT00768300. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ARTEMIS-IPF: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Early Idiopathic Pulmonary Fibrosis (IPF)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The ARTEMIS-IPF study was conducted to determine if ambrisentan was effective in delaying disease progression and death in participants with idiopathic pulmonary fibrosis (IPF), to evaluate its safety, and to evaluate its effect on development of pulmonary hypertension, quality of life, and dyspnea (shortness of breath) symptoms in this participant population. Participants were randomized in a 2:1 ratio to receive ambrisentan or placebo, respectively. Participation in the study was to be up to 4 years, depending on how long it would take to enroll participants and observe study events. After randomization, visits to the clinic took place every 3 months, and laboratory procedures were performed every month.
Study identification
- NCT ID
- NCT00768300
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 494 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2008
- Primary completion
- Jan 31, 2011
- Completion
- Jan 31, 2011
- Last update posted
- Apr 7, 2014
2008 – 2011
United States locations
- U.S. sites
- 57
- U.S. states
- 28
- U.S. cities
- 51
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Hospital | Birmingham | Alabama | 35294 | — |
| Pulmonary Associates | Phoenix | Arizona | 85006 | — |
| Not listed | Scottsdale | Arizona | 85258 | — |
| David Geffen School of Medicine at UCLA(Harbor-UCLA Medical Center) | Los Angeles | California | 90095 | — |
| University of California, Davis | Sacramento | California | 95817 | — |
| Not listed | San Diego | California | 92103-8373 | — |
| Not listed | San Francisco | California | 94143 | — |
| Stanford University | Stanford | California | 94305 | — |
| National Jewish Medical And Research Center | Denver | Colorado | 80206 | — |
| Not listed | Newark | Delaware | 19713 | — |
| Bay Area Chest Physicians | Clearwater | Florida | 33756 | — |
| University of Miami Miller School of Medicine | Miami | Florida | 33136 | — |
| Not listed | Tampa | Florida | 33606 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Not listed | Council Bluffs | Iowa | 51503 | — |
| Kentuckiana Pulmonary Association | Louisville | Kentucky | 40202 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | Baltimore | Maryland | 21201 | — |
| Not listed | Baltimore | Maryland | 21205 | — |
| Not listed | Boston | Massachusetts | 02115 | — |
| Not listed | Boston | Massachusetts | 02215 | — |
| Not listed | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Saint Lukes Foundation | Chesterfield | Missouri | 63017 | — |
| Dartmouth Medical School | Lebanon | New Hampshire | 03756 | — |
| Not listed | New Brunswick | New Jersey | 08903 | — |
| Not listed | Piscataway | New Jersey | 08854 | — |
| Pulmonary & Allergy Associates | Summit | New Jersey | 07091 | — |
| Pulmonary And Critical Care Services, P.C. | Albany | New York | 12205 | — |
| Winthrop University Hospital | Mineola | New York | 11501 | — |
| Not listed | New Hyde Park | New York | 11040 | — |
| Not listed | New York | New York | 10029 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Not listed | Cincinnati | Ohio | 45267 | — |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44795 | — |
| Not listed | Columbus | Ohio | 43215 | — |
| The Oregon Clinic, P.C. | Portland | Oregon | 97220 | — |
| University of Pennsylvania Health Systems | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Philadelphia | Pennsylvania | 19140 | — |
| Not listed | Pittsburgh | Pennsylvania | 15212 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| The Reading Hospital and Medical Center | Reading | Pennsylvania | 19611 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Not listed | Lexington | South Carolina | 29072 | — |
| Not listed | Spartanburg | South Carolina | 29303 | — |
| Not listed | Nashville | Tennessee | 37232 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | McKinney | Texas | 75069 | — |
| Not listed | Provo | Utah | 84604 | — |
| Not listed | Salt Lake City | Utah | 84108 | — |
| Not listed | Charlottesville | Virginia | 22908 | — |
| Not listed | Falls Church | Virginia | 22042 | — |
| Not listed | Lynchburg | Virginia | 24501 | — |
| Not listed | Everett | Washington | 98201 | — |
| Not listed | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 128 non-U.S. sites.
Recently updated Idiopathic Pulmonary Fibrosis trials
Other public records listing Idiopathic Pulmonary Fibrosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT06325696: H01 in Adults With Interstitial Lung Disease (The SOLIS Study) Recruiting
- NCT05389215: Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF Active, not recruiting
- NCT07671911: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets Recruiting
- NCT07674745: Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis Not yet recruiting
- NCT05241275: Xenon MRI and Progressive ILD Active, not recruiting
- NCT00470327: A Study of the Natural Progression of Interstitial Lung Disease (ILD) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00768300, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 7, 2014 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00768300 live on ClinicalTrials.gov.